<?xml version="1.0" encoding="UTF-8"?>
<ref id="B45">
 <label>45</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Michael Gibson</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Korjian</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Tricoci</surname>
    <given-names>P.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I event reducing in ischemic syndromes I)</article-title>
  <source>
   <italic toggle="yes">Circulation</italic>
  </source>
  <year>2016</year>
  <volume>134</volume>
  <issue>24</issue>
  <fpage>1918</fpage>
  <lpage>1930</lpage>
  <pub-id pub-id-type="doi">10.1161/circulationaha.116.025687</pub-id>
  <pub-id pub-id-type="other">2-s2.0-84996938010</pub-id>
  <pub-id pub-id-type="pmid">27881559</pub-id>
 </element-citation>
</ref>
